SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd. (SLGL) is expected to report earnings on November 10, 2026, before the market open. The consensus earnings estimate is a loss of $1.71 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -23.9% since its last earnings release on August 20, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Sol-Gel Technologies Ltd.
Sol-Gel is a dermatology company focused on identifying, developing and commercializing or partnering drug products for the treatment of skin diseases.
Sector
Healthcare
Industry
Drugs - Generic
Charts powered in part by Lightweight Charts™ by TradingView.